China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]
China Molecular Diagnostics Market is projected to reach US$ 1.8 Billion by the end of year 2024. Molecular diagnostics is a technique which is used for the molecular biological detection of any change in the structure or expression of patient’s genetic material. Molecular diagnostics plays an essential role in the detection and identification of various diseases and has gained more public & healthcare specialist attention than ever before. Today, Molecular diagnostics is changing the face of clinical laboratories by offering easy to use automated molecular systems that provide rapid results with less hands-on time.
China Molecular Diagnostics Market is growing rapidly due to the rising incidence of cancer and infectious diseases in the region. In addition; growing wealthy middle class population, who now are willing to pay more in availing better healthcare facilities and aging population who are more vulnerable to communicable diseases and the development in Chinese healthcare infrastructure are some other factors which are expected to drive China Molecular Diagnostics Market to a new record in the forthcoming years.
Renub Research report titled “China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]” provides a complete analysis of China Molecular Diagnostics Market.
By Application – Oncology and Infectious Disease Driving the China Molecular Diagnostics Market
The report studies the market and volume of the following Molecular Diagnostics segments: Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV) and Genetic Disease Testing (Blood Screening, HLA). Due to the rising cancer cases and infectious diseases in the China, it is believed that Oncology testing and Infectious disease testing leads the China Molecular Diagnostics Market in terms of both market & volume.
The report China Molecular Diagnostics Market has been studied from 7 viewpoints:
1) Market & Forecast
2) Volume & Forecast
3) Segments – Market Share & Forecast
4) Segments – Volume Share & Forecast
5) Profiles of Private Clinical Labs and Diagnostic Services
6) Growth Drivers for China Molecular Diagnostics
7) Challenges for China Molecular Diagnostics
This market research report provides a complete analysis of the China Molecular Diagnostics Market, Volume, Growth Drivers, Challenges, and their projections for the upcoming years.
Segment Covered in this report are as follows:
Oncology Testing Market and Volume
China Molecular Diagnostics Market is growing rapidly due to the rising incidence of cancer and infectious diseases in the region. In addition; growing wealthy middle class population, who now are willing to pay more in availing better healthcare facilities and aging population who are more vulnerable to communicable diseases and the development in Chinese healthcare infrastructure are some other factors which are expected to drive China Molecular Diagnostics Market to a new record in the forthcoming years.
Renub Research report titled “China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]” provides a complete analysis of China Molecular Diagnostics Market.
By Application – Oncology and Infectious Disease Driving the China Molecular Diagnostics Market
The report studies the market and volume of the following Molecular Diagnostics segments: Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV) and Genetic Disease Testing (Blood Screening, HLA). Due to the rising cancer cases and infectious diseases in the China, it is believed that Oncology testing and Infectious disease testing leads the China Molecular Diagnostics Market in terms of both market & volume.
The report China Molecular Diagnostics Market has been studied from 7 viewpoints:
1) Market & Forecast
2) Volume & Forecast
3) Segments – Market Share & Forecast
4) Segments – Volume Share & Forecast
5) Profiles of Private Clinical Labs and Diagnostic Services
6) Growth Drivers for China Molecular Diagnostics
7) Challenges for China Molecular Diagnostics
This market research report provides a complete analysis of the China Molecular Diagnostics Market, Volume, Growth Drivers, Challenges, and their projections for the upcoming years.
Segment Covered in this report are as follows:
Oncology Testing Market and Volume
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Virology
- HPV
- Blood Screening
- HLA
- Zhejiang Di’an Diagnostics Technology Co., Ltd
- ADICON Clinical Laboratories
- Guangzhou Kingmed Diagnostics Center Co. Ltd.
- Kindstar Global (Privately held)
- BGI-Shenzhen (Privately held)
- OriGene Technologies (Privately held)
1. EXECUTIVE SUMMARY
2. CHINA MOLECULAR DIAGNOSTIC MARKET & TEST VOLUME
2.1 China Molecular Diagnostic Market
2.2 China Molecular Diagnostic Test Volume
3. MARKET SHARE – CHINA MOLECULAR DIAGNOSTIC VOLUME SHARE ANALYSIS
3.1 Segments
3.2 Disease
3.3 Oncology Test
3.4 Genetic Test
3.5 Infectious Disease Test
4. VOLUME SHARE – CHINA MOLECULAR DIAGNOSTICS
4.1 Segments
4.2 Disease
4.3 Oncology Test
4.4 Infectious Disease Test
4.5 Genetic Test
5. DISEASE – CHINA MOLECULAR DIAGNOSTIC TEST VOLUME
5.1 Oncology Test Volume
5.1.1 Breast Cancer Test Volume
5.1.2 Colorectal Cancer Test Volume
5.1.3 Prostate Cancer Test Volume
5.2 Infectious Disease Test Volume
5.2.1 Virology Test Volume
5.2.2 HPV Test Volume
5.3 Genetic Test Volume
5.3.1 Blood Screening Test Volume
5.3.2 HLA Test Volume
6. DISEASE – CHINA MOLECULAR DIAGNOSTIC MARKET
6.1 Oncology Testing Market
6.1.1 Breast Cancer Testing Market
6.1.2 Colorectal Cancer Testing Market
6.1.3 Prostate Cancer Testing Market
6.2 Infectious Disease Testing Market
6.2.1 Virology Testing Market
6.2.2 HPV Testing Market
6.3 Genetic Testing Market
6.3.1 Blood Screening Market
6.3.2 HLA Testing Market
7. CHINA HEALTHCARE INSURANCE SCHEMES
7.1 China Healthcare Insurance Schemes
7.1.1 New Rural Cooperative Medical Scheme (NRCMS)
7.1.2 Urban Employed Basic Medical Insurance (UEBMI)
7.1.3 Urban Resident Basic Medical Insurance (URBMI)
7.1.4 Private Health Insurance
8. GROWTH DRIVERS
8.1 Increasing Demand from Middle Class for High Quality Healthcare Products
8.2 Rising Incidences of Lifestyle Diseases in China
8.3 Rapid Development in the Diagnosis of Infectious Diseases in China
8.4 Growth in Private Hospitals & Independent Diagnostic Centers
8.4.1 Increasing the Number of Hospital Beds across all Medical Institutions
9. CHALLENGES
9.1 Lack of Government Support, Public Awareness for Molecular Diagnostics test
9.2 Shortage of Skilled Technicians in China
9.3 Reimbursement Rates varies from Province to Province in China
9.3.1 Chinese Government Regulating Laboratory Testing in China
10. PROFILES OF PRIVATE CLINICAL LABS AND DIAGNOSTIC SERVICES COMPANIES
10.1 Zhejiang Di’an Diagnostics Technology Co., Ltd.
10.1.1 Company Overview
10.1.2 Products and Services Offered by Di’an
10.2 ADICON Clinical Laboratories (Privately held)
10.2.1 Company Overview
10.2.2 Products and Services Offered by ADICON
10.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
10.3.1 Company Overview
10.3.2 Products and Services Offered by Kingmed
10.4 Kindstar Global (Privately held)
10.4.1 Company Overview
10.4.2 Products and Services Offered by Kindstar
10.5 BGI–Shenzhen
10.5.1 Company Overview
10.5.2 BGI’s Innovative Approach
10.6 OriGene Technologies
10.6.1 Company Overview
10.6.2 Products and Services Offered by OriGene
2. CHINA MOLECULAR DIAGNOSTIC MARKET & TEST VOLUME
2.1 China Molecular Diagnostic Market
2.2 China Molecular Diagnostic Test Volume
3. MARKET SHARE – CHINA MOLECULAR DIAGNOSTIC VOLUME SHARE ANALYSIS
3.1 Segments
3.2 Disease
3.3 Oncology Test
3.4 Genetic Test
3.5 Infectious Disease Test
4. VOLUME SHARE – CHINA MOLECULAR DIAGNOSTICS
4.1 Segments
4.2 Disease
4.3 Oncology Test
4.4 Infectious Disease Test
4.5 Genetic Test
5. DISEASE – CHINA MOLECULAR DIAGNOSTIC TEST VOLUME
5.1 Oncology Test Volume
5.1.1 Breast Cancer Test Volume
5.1.2 Colorectal Cancer Test Volume
5.1.3 Prostate Cancer Test Volume
5.2 Infectious Disease Test Volume
5.2.1 Virology Test Volume
5.2.2 HPV Test Volume
5.3 Genetic Test Volume
5.3.1 Blood Screening Test Volume
5.3.2 HLA Test Volume
6. DISEASE – CHINA MOLECULAR DIAGNOSTIC MARKET
6.1 Oncology Testing Market
6.1.1 Breast Cancer Testing Market
6.1.2 Colorectal Cancer Testing Market
6.1.3 Prostate Cancer Testing Market
6.2 Infectious Disease Testing Market
6.2.1 Virology Testing Market
6.2.2 HPV Testing Market
6.3 Genetic Testing Market
6.3.1 Blood Screening Market
6.3.2 HLA Testing Market
7. CHINA HEALTHCARE INSURANCE SCHEMES
7.1 China Healthcare Insurance Schemes
7.1.1 New Rural Cooperative Medical Scheme (NRCMS)
7.1.2 Urban Employed Basic Medical Insurance (UEBMI)
7.1.3 Urban Resident Basic Medical Insurance (URBMI)
7.1.4 Private Health Insurance
8. GROWTH DRIVERS
8.1 Increasing Demand from Middle Class for High Quality Healthcare Products
8.2 Rising Incidences of Lifestyle Diseases in China
8.3 Rapid Development in the Diagnosis of Infectious Diseases in China
8.4 Growth in Private Hospitals & Independent Diagnostic Centers
8.4.1 Increasing the Number of Hospital Beds across all Medical Institutions
9. CHALLENGES
9.1 Lack of Government Support, Public Awareness for Molecular Diagnostics test
9.2 Shortage of Skilled Technicians in China
9.3 Reimbursement Rates varies from Province to Province in China
9.3.1 Chinese Government Regulating Laboratory Testing in China
10. PROFILES OF PRIVATE CLINICAL LABS AND DIAGNOSTIC SERVICES COMPANIES
10.1 Zhejiang Di’an Diagnostics Technology Co., Ltd.
10.1.1 Company Overview
10.1.2 Products and Services Offered by Di’an
10.2 ADICON Clinical Laboratories (Privately held)
10.2.1 Company Overview
10.2.2 Products and Services Offered by ADICON
10.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
10.3.1 Company Overview
10.3.2 Products and Services Offered by Kingmed
10.4 Kindstar Global (Privately held)
10.4.1 Company Overview
10.4.2 Products and Services Offered by Kindstar
10.5 BGI–Shenzhen
10.5.1 Company Overview
10.5.2 BGI’s Innovative Approach
10.6 OriGene Technologies
10.6.1 Company Overview
10.6.2 Products and Services Offered by OriGene
LIST OF FIGURES
Figure 2–1: China – Molecular Diagnostic Market (Billion US$), 2011 – 2017
Figure 2–2: China – Forecast for Molecular Diagnostic Market (Billion US$), 2018 – 2024
Figure 2–3: China – Molecular Diagnostic Test Volume (Million), 2011 – 2017
Figure 2–4: China – Forecast for Molecular Diagnostic Test Volume (Million), 2018 – 2024
Figure 3–1: China – Molecular Diagnostic Market Share (Percent), 2011 – 2017
Figure 3–2: China – Forecast for Molecular Diagnostic Market Share (Percent), 2018 – 2024
Figure 3–3: China – Molecular Oncology Test Market Share (Percent), 2011 – 2017
Figure 3–4: China – Forecast for Molecular Oncology Test Market Share (Percent), 2018 – 2024
Figure 4–1: China – Molecular Diagnostic Test Volume Share (Percent), 2011 – 2017
Figure 4–2: China – Forecast for Molecular Diagnostic Test Volume Share (Percent), 2018 – 2024
Figure 4–3: China – Molecular Oncology Test Volume Share (Percent), 2011 – 2017
Figure 4–4: China – Forecast for Molecular Oncology Test Volume Share (Percent), 2018 – 2024
Figure 5–1: Rural China – Cancer Screening Sites by Cancer Type (Number), 2013
Figure 5–2: China – Oncology Test Volume (Million), 2011 – 2017
Figure 5–3: China – Forecast for Oncology Test Volume (Million), 2018 – 2024
Figure 5–4: China –Breast Cancer Molecular Test Volume (Million), 2011 – 2017
Figure 5–5: China – Forecast for Breast Cancer Molecular Test Volume (Million), 2018 – 2024
Figure 5–6: China – Colorectal Cancer Test Volume (Million), 2011 – 2017
Figure 5–7: China – Forecast for Colorectal Cancer Test Volume (Million), 2018 – 2024
Figure 5–8: China –Prostate Cancer Test Volume (Million), 2011 – 2017
Figure 5–9: China – Forecast for Prostate Cancer Test Volume (Million), 2018 – 2024
Figure 5–10: China – Infectious Disease Test Volume (Million), 2011 – 2017
Figure 5–11: China – Forecast for Infectious Disease Test Volume (Million), 2018 – 2024
Figure 5–12: China –Virology Test Volume (Million), 2011 – 2017
Figure 5–13: China – Forecast for Virology Test Volume (Million), 2018 – 2024
Figure 5–14: China –HPV Test Volume (Thousand), 2011 – 2017
Figure 5–15: China – Forecast for HPV Test Volume (Thousand), 2018 – 2024
Figure 5–16: China –Genetic Test Volume (Million), 2011 – 2017
Figure 5–17: China – Forecast for Genetic Test Volume (Million), 2018 – 2024
Figure 5–18: China –Blood Screening Test Volume (Million), 2011 – 2017
Figure 5–19: China – Forecast for Blood Screening Test Volume (Million), 2018 – 2024
Figure 5–20: China – HLA Test Volume (Thousand), 2011 – 2017
Figure 5–21: China – Forecast for HLA Test Volume (Thousand), 2018 – 2024
Figure 6–1: China –Oncology Testing Market (Million US$), 2011 – 2017
Figure 6–2: China – Forecast for Oncology Testing Market (Million US$), 2018 – 2024
Figure 6–3: China –Breast Cancer Testing Market (Million US$), 2011 – 2017
Figure 6–4: China – Forecast for Breast Cancer Testing Market (Million US$), 2018 – 2024
Figure 6–5: China –Colorectal Cancer Testing Market (Million US$), 2011 – 2017
Figure 6–6: China – Forecast for Colorectal Cancer Testing Market (Million US$), 2018 – 2024
Figure 6–7: China –Prostate Cancer Testing Market (Million US$), 2011 – 2017
Figure 6–8: China – Forecast for Prostate Cancer Testing Market (Million US$), 2018 – 2024
Figure 6–9: China –Infectious Disease Testing Market (Million US$), 2011 – 2017
Figure 6–10: China – Forecast for Infectious Disease Testing Market (Million US$), 2018 – 2024
Figure 6–11: China –Virology Testing Market (Million US$), 2011 – 2017
Figure 6–12: China – Forecast for Virology Testing Market (Million US$), 2018 – 2024
Figure 6–13: China –HPV Testing Market (Million US$), 2011 – 2017
Figure 6–14: China – Forecast for HPV Testing Market (Million US$), 2018 – 2024
Figure 6–15: China –Genetic Testing Market (Million US$), 2011 – 2017
Figure 6–16: China – Forecast for Genetic Testing Market (Million US$), 2018 – 2024
Figure 6–17: China –Blood Screening Market (Million US$), 2011 – 2017
Figure 6–18: China – Forecast for Blood Screening Market (Million US$), 2018 – 2024
Figure 6–19: China – HLA Testing Market (Thousand US$), 2011 – 2017
Figure 6–20: China – Forecast for HLA Testing Market (Thousand US$), 2018 – 2024
Figure 8–1: China – Healthcare Spending (Billion US$), 2011 & 2020
Figure 10–1: Kindstar – Collaboration with Hospitals in China (Number), 2006 – 2012
Figure 2–1: China – Molecular Diagnostic Market (Billion US$), 2011 – 2017
Figure 2–2: China – Forecast for Molecular Diagnostic Market (Billion US$), 2018 – 2024
Figure 2–3: China – Molecular Diagnostic Test Volume (Million), 2011 – 2017
Figure 2–4: China – Forecast for Molecular Diagnostic Test Volume (Million), 2018 – 2024
Figure 3–1: China – Molecular Diagnostic Market Share (Percent), 2011 – 2017
Figure 3–2: China – Forecast for Molecular Diagnostic Market Share (Percent), 2018 – 2024
Figure 3–3: China – Molecular Oncology Test Market Share (Percent), 2011 – 2017
Figure 3–4: China – Forecast for Molecular Oncology Test Market Share (Percent), 2018 – 2024
Figure 4–1: China – Molecular Diagnostic Test Volume Share (Percent), 2011 – 2017
Figure 4–2: China – Forecast for Molecular Diagnostic Test Volume Share (Percent), 2018 – 2024
Figure 4–3: China – Molecular Oncology Test Volume Share (Percent), 2011 – 2017
Figure 4–4: China – Forecast for Molecular Oncology Test Volume Share (Percent), 2018 – 2024
Figure 5–1: Rural China – Cancer Screening Sites by Cancer Type (Number), 2013
Figure 5–2: China – Oncology Test Volume (Million), 2011 – 2017
Figure 5–3: China – Forecast for Oncology Test Volume (Million), 2018 – 2024
Figure 5–4: China –Breast Cancer Molecular Test Volume (Million), 2011 – 2017
Figure 5–5: China – Forecast for Breast Cancer Molecular Test Volume (Million), 2018 – 2024
Figure 5–6: China – Colorectal Cancer Test Volume (Million), 2011 – 2017
Figure 5–7: China – Forecast for Colorectal Cancer Test Volume (Million), 2018 – 2024
Figure 5–8: China –Prostate Cancer Test Volume (Million), 2011 – 2017
Figure 5–9: China – Forecast for Prostate Cancer Test Volume (Million), 2018 – 2024
Figure 5–10: China – Infectious Disease Test Volume (Million), 2011 – 2017
Figure 5–11: China – Forecast for Infectious Disease Test Volume (Million), 2018 – 2024
Figure 5–12: China –Virology Test Volume (Million), 2011 – 2017
Figure 5–13: China – Forecast for Virology Test Volume (Million), 2018 – 2024
Figure 5–14: China –HPV Test Volume (Thousand), 2011 – 2017
Figure 5–15: China – Forecast for HPV Test Volume (Thousand), 2018 – 2024
Figure 5–16: China –Genetic Test Volume (Million), 2011 – 2017
Figure 5–17: China – Forecast for Genetic Test Volume (Million), 2018 – 2024
Figure 5–18: China –Blood Screening Test Volume (Million), 2011 – 2017
Figure 5–19: China – Forecast for Blood Screening Test Volume (Million), 2018 – 2024
Figure 5–20: China – HLA Test Volume (Thousand), 2011 – 2017
Figure 5–21: China – Forecast for HLA Test Volume (Thousand), 2018 – 2024
Figure 6–1: China –Oncology Testing Market (Million US$), 2011 – 2017
Figure 6–2: China – Forecast for Oncology Testing Market (Million US$), 2018 – 2024
Figure 6–3: China –Breast Cancer Testing Market (Million US$), 2011 – 2017
Figure 6–4: China – Forecast for Breast Cancer Testing Market (Million US$), 2018 – 2024
Figure 6–5: China –Colorectal Cancer Testing Market (Million US$), 2011 – 2017
Figure 6–6: China – Forecast for Colorectal Cancer Testing Market (Million US$), 2018 – 2024
Figure 6–7: China –Prostate Cancer Testing Market (Million US$), 2011 – 2017
Figure 6–8: China – Forecast for Prostate Cancer Testing Market (Million US$), 2018 – 2024
Figure 6–9: China –Infectious Disease Testing Market (Million US$), 2011 – 2017
Figure 6–10: China – Forecast for Infectious Disease Testing Market (Million US$), 2018 – 2024
Figure 6–11: China –Virology Testing Market (Million US$), 2011 – 2017
Figure 6–12: China – Forecast for Virology Testing Market (Million US$), 2018 – 2024
Figure 6–13: China –HPV Testing Market (Million US$), 2011 – 2017
Figure 6–14: China – Forecast for HPV Testing Market (Million US$), 2018 – 2024
Figure 6–15: China –Genetic Testing Market (Million US$), 2011 – 2017
Figure 6–16: China – Forecast for Genetic Testing Market (Million US$), 2018 – 2024
Figure 6–17: China –Blood Screening Market (Million US$), 2011 – 2017
Figure 6–18: China – Forecast for Blood Screening Market (Million US$), 2018 – 2024
Figure 6–19: China – HLA Testing Market (Thousand US$), 2011 – 2017
Figure 6–20: China – Forecast for HLA Testing Market (Thousand US$), 2018 – 2024
Figure 8–1: China – Healthcare Spending (Billion US$), 2011 & 2020
Figure 10–1: Kindstar – Collaboration with Hospitals in China (Number), 2006 – 2012
LIST OF TABLES
Table 3–1: China – Molecular Diagnostic Application Market Share (Percent), 2011 – 2017
Table 3–2: China – Forecast for Molecular Diagnostic Application Market Share (Percent), 2018 – 2024
Table 3–3: China – Molecular Genetic Test Market Share (Percent), 2011 – 2017
Table 3–4: China – Forecast for Molecular Genetic Test Market Share (Percent), 2018 – 2024
Table 3–5: China – Molecular Infectious Disease Test Market Share (Percent), 2011 – 2017
Table 3–6: China – Forecast for Molecular Infectious Disease Test Market Share (Percent), 2018 – 2024
Table 4–1: China – Molecular Diagnostic Test Volume Application Share (Percent), 2011 – 2017
Table 4–2: China – Forecast for Molecular Diagnostic Test Volume Application Share (Percent), 2018 – 2024
Table 4–3: China – Molecular Infectious Disease Test Volume Share (Percent), 2011 – 2017
Table 4–4: China – Forecast for Molecular Infectious Disease Test Volume Share (Percent), 2018 – 2024
Table 4–5: China – Molecular Genetic Test Volume Share (Percent), 2011 – 2017
Table 4–6: China – Forecast for Molecular Genetic Test Volume Share (Percent), 2018 – 2024
Table 8–1: China – Major Diagnostic Reagent R&D and Manufacturing Companies in Infectious Diseases, 2010
Table 8-2: Number of hospital beds for every 1,000 people
Table 3–1: China – Molecular Diagnostic Application Market Share (Percent), 2011 – 2017
Table 3–2: China – Forecast for Molecular Diagnostic Application Market Share (Percent), 2018 – 2024
Table 3–3: China – Molecular Genetic Test Market Share (Percent), 2011 – 2017
Table 3–4: China – Forecast for Molecular Genetic Test Market Share (Percent), 2018 – 2024
Table 3–5: China – Molecular Infectious Disease Test Market Share (Percent), 2011 – 2017
Table 3–6: China – Forecast for Molecular Infectious Disease Test Market Share (Percent), 2018 – 2024
Table 4–1: China – Molecular Diagnostic Test Volume Application Share (Percent), 2011 – 2017
Table 4–2: China – Forecast for Molecular Diagnostic Test Volume Application Share (Percent), 2018 – 2024
Table 4–3: China – Molecular Infectious Disease Test Volume Share (Percent), 2011 – 2017
Table 4–4: China – Forecast for Molecular Infectious Disease Test Volume Share (Percent), 2018 – 2024
Table 4–5: China – Molecular Genetic Test Volume Share (Percent), 2011 – 2017
Table 4–6: China – Forecast for Molecular Genetic Test Volume Share (Percent), 2018 – 2024
Table 8–1: China – Major Diagnostic Reagent R&D and Manufacturing Companies in Infectious Diseases, 2010
Table 8-2: Number of hospital beds for every 1,000 people
